Clinical trials: Lung Cancer Recurrent
Lung Cancer
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00520845
- Testing
- celecoxib, Docetaxel, pemetrexed disodium
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Lung Cancer, Non-Small Cell
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to…
- Trial name
- NCT06405230
- Testing
- Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin)
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Malignant Mesothelioma
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant…
- Trial name
- NCT00005636
- Testing
- cisplatin, pemetrexed disodium
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer, Breast Cancer
Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study
Sometimes, cancer comes back after it has been successfully treated-a situation called recurrent cancer. When recurrent cancer is suspected, the standard approach to diagnosis is to perform a combination of imaging tests, such as…
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- PETREC (NCT00686465)
- Testing
- PET/CT scan
- Where
- 4 sites in Canada
- Volunteers
- 101 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy.
- Trial name
- NCT00017407
- Testing
- ISIS 3521, carboplatin, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
This phase II trial is studying how well RO4929097 works in treating patients with advanced non-small cell lung cancer who have recently completed treatment with front-line chemotherapy.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01193868
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC Stage IV, NSCLC, Recurrent
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
- Trial name
- NCT04467723
- Testing
- Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Mesothelioma
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated…
- Trial name
- NCT00509041
- Testing
- dasatinib
- Where
- 37 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
EGFR Activating Mutation, NSCLC Stage IV
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
This is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as…
- Conditions
- EGFR Activating Mutation, NSCLC Stage IV, NSCLC Stage IIIB, NSCLC, Recurrent
- Trial name
- NCT04768491
- Testing
- Dacomitinib
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Peking Union Medical College
Breast Cancer, Lung Cancer
Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90-DOTA-tyr3-octreotide can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006370
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol.
- Trial name
- NCT00033722
- Testing
- folic acid, lometrexol
- Where
- 7 sites in United States
- Sponsor
- Tularik
Non-Small Cell Lung Cancer
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day cycles. Subjects will continue until disease progression is documented.
- Trial name
- NCT00179686
- Testing
- CC-5013
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Mediastinal Neoplasms
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
The purposes of this study are: To determine the overall response rate of patients treated with at least 2 cycles of this regimen. To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
- Trial name
- NCT00315211
- Testing
- Intravenous Topotecan, Intravenous Docetaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Aultman Health Foundation
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Cognitive/Functional Effects, Delirium
Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer
RATIONALE: Donepezil and vitamin E may be able to decrease side effects caused by radiation therapy given to prevent brain metastases in patients with small cell lung cancer.
- Conditions
- Cognitive/Functional Effects, Delirium, Depression, Lung Cancer
- Trial name
- NCT00006349
- Testing
- vitamin E, donepezil hydrochloride
- Where
- 15 sites in United States
- Volunteers
- 9 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
TR(ACE) Assay Clinical Specimen Study
The TR(ACE) Assay is a quantitative in vitro diagnostic test run on the TR(ACE) Instrument intended for the measurement of high molecular weight human DNA from plasma as an aid to monitoring disease progression or response to…
- Trial name
- NCT02934360
- Testing
- TR(ACE) Assay Testing
- Where
- 16 sites in United States
- Volunteers
- 450 people
- Sponsor
- Biological Dynamics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.